Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-News: Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
EQS-News: Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
EQS-News: Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
EQS-News: Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
EQS-News: Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
EQS-News: Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
Premier, Inc. Application Is Under Construction in Epic Toolbox
Premier, Inc. Application Is Under Construction in Epic Toolbox


Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today that one of its AI-powered applications, Stanson Health CodingCare, is Under Construction in Toolbox on Epic

Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development
Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development


Charles River Laboratories International, Inc. (NYSE: CRL), ahead of the American Association for Cancer Research® (AACR) Annual Meeting in Chicago, IL, has announced updates to its comprehensive

Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer


Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two oral presentations and a poster presentation featuring data for the company’s NeXT

Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies


Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical

Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 12, 2025
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 12, 2025


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

Sonova concludes 2022-25 share buyback
Sonova concludes 2022-25 share buyback
Sonova concludes 2022-25 share buyback
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference


Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product

Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma


Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the

Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28Photo, wide shot, wide-angle lens,  Home appliance manufacturer, neutral atmosphere, photo by Joe Cornish: https://img.theapi.app/temp/fb3845ac-e3c6-43ef-86c1-b57ed8c272c4.png
Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28


Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host

ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease


Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for

New Report from the Humana Foundation Examines Best-Practices in Community-Engaged Research
New Report from the Humana Foundation Examines Best-Practices in Community-Engaged Research


The Humana Foundation, the philanthropic arm of Humana Inc. for the past 44 years, today announced the publication of its new report, Strengthening Science and Community Impact Through Equitable

Acadia Healthcare Announces Date for First Quarter 2025 Earnings Release
Acadia Healthcare Announces Date for First Quarter 2025 Earnings Release


Acadia Healthcare (NASDAQ: ACHC) (“Acadia” or the “Company”) today announced that it will release its first quarter 2025 financial results on Monday, May 12, 2025, after the close of the market

Inogen to Report First Quarter 2025 Financial Results on May 7, 2025
Inogen to Report First Quarter 2025 Financial Results on May 7, 2025


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2025 financial

Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025:
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025


Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at

Sensorion to Host a Symposium during ISIET’s International Conference on Inner Ear Therapies on April 26, 2025
Sensorion to Host a Symposium during ISIET’s International Conference on Inner Ear Therapies on April 26, 2025


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

Sartorius Stedim Biotech publishes unaudited first quarter results for 2025
Sartorius Stedim Biotech publishes unaudited first quarter results for 2025
Sartorius Stedim Biotech publishes unaudited first quarter results for 2025
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call


Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2025 financial results on Wednesday, May 7th, before the market opens. A conference call has been scheduled to

Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron


Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated

Savara Announces New Employment Inducement Grant
Savara Announces New Employment Inducement Grant


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to seven new employees.



On April 9

Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month


Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced donations totaling $1.5 million to multiple patient assistance

EQS-News:  Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024
EQS-News: Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024
EQS-News: Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024
Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24


Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2025 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 24